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Targeting p53 and histone methyltransferases
restores exhausted CD8+ T cells in HCV infection
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Hepatitis C virus infection (HCV) represents a unique model to characterize, from early to
late stages of infection, the T cell differentiation process leading to exhaustion of human
CD8+ T cells. Here we show that in early HCV infection, exhaustion-committed virus-
specific CD8+ T cells display a marked upregulation of transcription associated with impaired
glycolytic and mitochondrial functions, that are linked to enhanced ataxia-telangiectasia
mutated (ATM) and p53 signaling. After evolution to chronic infection, exhaustion of HCV-
specific T cell responses is instead characterized by a broad gene downregulation associated
with a wide metabolic and anti-viral function impairment, which can be rescued by histone
methyltransferase inhibitors. These results have implications not only for treatment of HCV-
positive patients not responding to last-generation antivirals, but also for other chronic
pathologies associated with T cell dysfunction, including cancer.
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Hepatitis C virus (HCV) infection can progress to resolu-tion in around 20–40% of the cases; conversely, in60–80% of infected patients the virus persists and the
infection becomes chronic. Therefore, patients with different
disease outcomes can be identified at early stages of infection
making hepatitis C an ideal model to study the process of dif-
ferentiation from early exhaustion-committed to late fully
exhausted CD8+ T cells in humans. Spontaneous viral clearance
is associated with efficient CD8+ T cell responses, whereas
cytotoxic T cells are functionally impaired in chronically infected
patients1,2. In chronic viral infections, including hepatitis C,
persistent antigen stimulation is believed to represent a major
determinant of CD8+ T cell dysfunction, which is characterized
by upregulation of multiple inhibitory receptors, repressive
transcriptional reprogramming, broad metabolic alterations and
defective T cell effector function and memory development3–9.
To improve exhausted T cell functions, regulatory pathway
manipulation has been attempted in various experimental set-
tings, but a full restoration has not been achieved so far5,10–12. It
is thus becoming increasingly clear that T cell exhaustion results
from a broader cellular alteration with an extensive involvement
of crucial T cell functions, including metabolism and epigenetic
regulation13–16. Indeed, the role of metabolic reprogramming in
T cell differentiation is now well appreciated6,15,17. In particular,
differentiation of naïve into effector T cells is accompanied by a
marked upregulation of aerobic glycolysis, to meet the increased
energetic demands associated with this transition18–20. Following
successful control of infection, glycolysis is turned down, and
mitochondrial fatty acid oxidation (FAO) becomes the major
provider of metabolic energy to support memory CD8+ T cell
generation, survival, and antigen recall responsiveness21,22.
Severe defects in HBV-specific CD8+ T cell mitochondrial
function (e.g., impaired FAO, ROS overproduction and mito-
chondrial depolarization) and the positive effect of their correc-
tion on CD8+ T cell exhaustion have recently been reported in
chronic HBV infection23,24. In the LCMV mouse model of
chronic infection, glycolysis downregulation and OXPHOS
impairment are hallmarks of exhaustion and are more evident in
the PD1hi than in the PD1int subset of exhausted CD8+ T cells25.
A dysregulated gene expression profile consistent with these
metabolic changes has recently been described in human HCV-
specific CD8+ T cells committed to exhaustion26, but a func-
tional assessment of the actual contribution of metabolic and
epigenetic state alteration to CD8+ T cell dysfunction and its
causal association with exhaustion is still lacking27.
To further delineate and functionally validate key dysregulated
pathways associated with the development of exhausted T cell
responses, we applied genome-wide transcriptome profiling,
coupled with multiple functional validation assays and targeted
rescue strategies, to virus-specific CD8+ T cells from chronically
evolving or resolved HCV infections. We show, here, that dif-
ferentiation from early exhaustion-committed to late fully
exhausted CD8+ T cells is marked by a transition from a pre-
dominantly upregulated early gene expression profile to a massive
late downregulation with global repression of core cellular pro-
cesses and an extensive histone methylation-dependent repressive
chromatin remodeling. Targeting dysfunctional signaling, meta-
bolic and chromatin remodeling pathways can efficiently improve
CD8+ T cell metabolism and antiviral function, and may thus
represent a novel rational immunomodulatory strategy, perhaps
complementary to PD-1 or other checkpoint inhibitor blockade,
to correct T cell exhaustion. This may positively impact HCV
infection, especially in ‘Direct Acting Antivirals’ (DAA) non-
responder patients who still require effective therapies, but also
other chronic diseases, including cancer, displaying T cell dys-
function caused by persistent CD8+ T cell stimulation.
Results
Early dysregulated metabolic and signaling pathways in HCV-
specific CD8+ T cells. We characterized CD8+ T cell gene
expression profiles associated with either spontaneous HCV
control and T cell memory generation or virus persistence and T
cell exhaustion. HCV-specific CD8+ T cells were collected and
sorted (Supplementary Fig. 1) from patients with T1/early self-
limited or chronically evolving acute HCV infection immediately
after clinical presentation (HCV RNA-positive patients, within
one month from the ALT peak; T1/early time-point) and at later
stages of resolution (HCV RNA-negative patients, at least
12 months after the ALT peak; T2/late time-point) or chronic
evolution of infection (HCV RNA-positive patients, followed for
at least one year after the first detection of ALT elevation; T2/late
time-point). Patients were thus subdivided into four groups,
designated as T1/early self-limited (n= 5), T1/early chronic (n=
8), T2/late resolved (late resolution phase of T1 self-limited
patients; n= 4) and T2/late-chronic (n= 7).
Principal-component analysis of ANOVA-filtered expression
data (Fig. 1a) revealed a significant overlap between the two groups
at the T1/early-stage time-point and a substantial separation
between T2 late-stage patients belonging to either the chronic (i.e.,
T cell-exhausted) or the fully resolved groups. This was confirmed
by the statistical clustering of gene expression data shown in Fig. 1b,
where the dysfunctional profiles of early and late exhausted CD8+
T cells appear to be distinct from that of FLU-specific CD8+ T cells
from healthy donors, which served as fully functional memory T cell
controls. Altogether, these results suggest a progressive, outcome-
dependent accumulation of divergent gene expression signatures
starting from more comparable acute phase transcriptional profiles.
A topology-based analysis, which relies not only on the
assignment of dysregulated genes to a given pathway but also on
gene connections derived from pathway annotation, was then
applied to the T1 and T2 datasets. Twenty-nine dysregulated
pathways (Benjamini-Hochberg corrected q-value ≤ 0.05) were
identified by this analysis in T1/early HCV-specific CD8+ T cells
from chronically evolving compared to self-limited acute patients
(Fig. 1c and Supplementary Data 1). By contrast, 277 dysregu-
lated pathways were retrieved by the same analysis from the T2/
late comparison of HCV-specific exhausted and memory CD8+
T cells from chronic and resolved patients, respectively. Fifteen of
these pathways were shared by the T1 and the T2 time-points
(Fig. 1c). Most of them (14 out of 15) were upregulated at the T1/
early-stage of chronically evolving infection but downregulated
(13 out of 15) at the T2/late-stage time-point (Fig. 1c). The
15 shared dysregulated pathways (Fig. 1c) include intracellular
signaling downstream to TCR activation, NF-kB/TNF activation,
DNA damage response and mitochondrion (MT)-related meta-
bolic functions as the most represented cellular processes (see
Supplementary Data 1). Half of the 14 T1/early-dysregulated
pathways, which were not shared with the T2/late time-point,
were downregulated. These comprised genes related to glucose
transport (GLUT1 and GLUT4, also known as SLC2A1 and
SLC2A4) and cytokine signaling, including the T cell-specific,
glycolysis-regulatory CD28 signaling pathway (Fig. 1d). Other
genes related to glucose homeostasis, including genes coding for
gluconeogenesis enzymes known to be involved in the production
of glycolytic intermediates under low glucose conditions28 (see
Supplementary Data 1), also emerged as enriched from topology-
based analysis.
The entire T1 dataset was then subjected to unsupervised gene-
set enrichment analysis (GSEA), which allows to reveal sets of
differentially regulated, functionally related genes, rather than
individual high-scoring genes, above an arbitrarily set cut-off. As
shown in Fig. 1e and Supplementary Fig. 2 (see also the T1 sheets
in Supplementary Data 2), all dysregulated pathways and gene
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ontology categories identified by GSEA were upregulated in
HCV-specific CD8+ T cells from T1/early chronic patients.
In particular, GSEA confirmed a strong upregulation of multiple
DNA damage response, intracellular signaling and cell-cycle
control genes, including immune-checkpoint inhibitors, such
as PD-1 (also known as PDCD1), CD160, CTLA4 and TIGIT
(see the T1 sheets in Supplementary Data 2). Notably, GSEA
also confirmed the upregulation of a large set of genes coding
for mitochondrial oxidative phosphorylation (OXPHOS) and
electron transport, reactive oxygen species (ROS) detoxification
and fatty acid oxidation (FAO) components (see Fig. 1e and
Supplementary Data 2). Further analysis of GSEA data using
the KEGG Reactome and GO databases allowed to group
T1 upregulated genes into eight distinct functional categories
matching the above mentioned dysregulated processes (Supple-
mentary Fig. 2).
A generalized upregulation thus appears to be the predominant
but not exclusive feature of acute-phase dysregulation.
Impaired CD8+ T cell glucose and mitochondrial metabolism
in early infection. To gain insight into the relationship between
a
c
b
FLU healthy
Acute HCV chronic evolution (T1)
HCV resolved (T2) HCV chronic (T2)
FLU healthy
Acute HCV chronic evolution (T1)
Acute HCV self-limited (T1)
HCV resolved (T2)
HCV chronic (T2) Signal
Cell cycle
DNA damage
DNA repair Cell signaling Mitochondrion 
-mTOR
signaling
-Downstream 
TCR signaling
-NFkB activation
-Jnk C-Jun 
Kinases 
phosphorylat. 
and activation
-Activation of 
ATR in 
response to 
replication 
stress
-Telomere 
maintenance
-p53 dependent 
G1 DNA 
damage 
response
-DNA repair
-TCA cycle and 
respiratory electron 
transport
-Oxidative phosphoryl.
-Mitochon. protein 
import
-Lipid oxidation
-DNA 
replication
-Cell cycle 
checkpoints
-Mitotic M-
G1 phases
HC
V
se
lf-l
im
ite
d
HC
V
ch
r. e
vo
l.
HC
V
se
lf-l
im
ite
d
HC
V
ch
r. e
vo
l.
HC
V
se
lf-l
im
ite
d
HC
V
ch
r. e
vo
l.
HC
V
se
lf-l
im
ite
d
HC
V
ch
r. e
vo
l.Signal
d
e
15
T1 = 29 T2 = 277
Adipocytokine signaling pathway
Alcoholism
Cell adhesion molecules (CAMs)
DNA damage/telomere stress induced senescence
Hepatitis C
Herpes simplex infection
Hypertrophic cardiomyopathy (HCM)
Metabolism of vitamins and cofactors
Metabolism of water-soluble vitamins and cofactors
NF-kappa B signaling pathway
RIG-I-like receptor signaling pathway
Shigellosis
Signaling by retinoic acid
T cell receptor signaling pathway
TNF signaling pathway
-T1 (Chronic-evol vs. self-lim) = 29 dysregulated pathways
Y-axis
X-axis
–40 –20 0 20 40 60
40
20
0
–40
–20
–60
–50
0
50
100
6040200–20–40
–60
–40
–20
0
20
40
100
50
0
–50
-T2 (Chronic vs. resolved) = 277 dysregulated pathways
T1 T2
Biotin transport and metabolism
CD28 co-stimulation
CD28 dependent PI3K/Akt signaling
Complement and coagulation cascades
Defensins
Epithelial cell signaling in helicobacter pylori infection
Glyoxylate and dicarboxylate metabolism
Metal ion SLC transporters
Mitochondrial fatty acid beta-oxidation
O-glycosylation of TSR domain-containing proteins
Propanoate metabolism
Regulatory RNA pathways
Scavenging by class A receptors
Synthesis of PA
T1
Up (red)
Down (blue)
14
T1 = 29 T2 = 277
–2.5 0 2.8
–2.0 0 2.0
Acute HCV self-limited (T1)
Z-axis
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14137-7 ARTICLE
NATURE COMMUNICATIONS |          (2020) 11:604 | https://doi.org/10.1038/s41467-019-14137-7 |www.nature.com/naturecommunications 3
the dysregulation of metabolism-related genes and progression
toward the exhaustion phenotype, GSEA analysis was applied
using the molecular signature identified in the murine model
of chronic LCMV infection25, obtained by merging the leading-
edge genes belonging to the different metabolic KEGG pathways.
As shown in Supplementary Fig. 3a, a significant overlap was
observed between metabolism-related genes that appear to be
dysregulated in early exhausted LCMV-specific lymphocytes and
in T1/early exhausted HCV-specific CD8+ T cells. Importantly,
in the case of the ‘glycolysis and gluconeogenesis’ and ‘oxidative
phosphorylation’ pathways, and of the ‘glucose deprivation
signature25,29, the correlation of the two datasets was confirmed
also when all genes (not only those restricted to the leading-edge
set) were considered (Supplementary Fig. 3b).
Particularly evident was a parallel enrichment in upregulated
genes related to mitochondrial metabolism and a concomitant
enrichment in downregulated, glycolysis-related genes at the T1
time-point, both of which were significantly correlated with the
relative expression levels of the same sets of genes in the LCMV
model of chronic infection (Pearson p-values < 0.05). Based on
these findings and on similar data reported for other models of
lymphocyte exhaustion29, we hypothesized that HCV-specific
CD8+ T cells from chronically evolving T1/early patients are in
shortage of glucose, which is required to meet the energy and
biosynthetic demands of T cell expansion.
To functionally verify T1/early metabolic gene dysregulation,
we initially focused on glucose metabolism and measured glucose
import, the first limiting step of glycolysis, as well as glucose
transporter 1 (GLUT1) protein levels. As shown in Fig. 2a–c,
glucose uptake and GLUT1 levels were both significantly reduced
in T1/early HCV-specific CD8+ T cells from chronically evolving
compared to self-limited patients and FLU-specific CD8+
controls. In line with these findings, also glucose consumption
was diminished in T1/early chronic CD8+ T cells compared to
control CD8+ T cells (Supplementary Fig. 4a).
The basal extracellular acidification rate (ECAR), a quantitative
indicator of glycolytic activity, as well as the maximum glycolytic
capacity and glycolytic reserve were also reduced in HCV
peptide-stimulated CD8+ T cells from chronically evolving T1/
early patients compared to control peptide (FLU, CMV and
EBV)-stimulated cells (see Fig. 2d and the cell energy phenotype
plots in Supplementary Fig. 4b). Conversely, NS3-HCV peptide
stimulated CD8+ T cells from T1/early acute self-limited patients
displayed higher ECAR values, both at basal and maximal
respiration levels, compared to CD8+ T cells derived from T1/
early chronically-evolving patients (see Fig. 2e and the cell energy
phenotype plots in Supplementary Fig. 4c).
Interestingly, in the same set of cells, expression levels of the
PD-1 co-inhibitor were inversely related to glucose uptake capacity
and were maximal in CD8+ T cells from T1/early chronically
evolving patients, thus suggesting a possible link between PD-1
upregulation and altered glucose metabolism (Supplementary
Fig. 4d).
HCV-specific CD8+ T cells from T1/early chronic patients also
displayed an impaired mitochondrial function. In fact, a markedly
reduced mitochondrial membrane potential (Fig. 3a) and abnor-
mally elevated mitochondrial ROS levels (Fig. 3b, c) were detected
in CD8+ T cells from chronically evolving patients. Further
confirming a depressed mitochondrial respiratory capacity, a
significantly lower basal oxygen consumption rate (OCR) and
similarly reduced maximal and spare respiratory capacities were
measured in purified HCV peptide-stimulated CD8+ T cells from
chronically evolving patients (see Fig. 3d and the cell energy
phenotype plots in Supplementary Fig. 4b). Again, NS3-HCV
peptide stimulated CD8+ T cells from T1/early acute self-limited
patients displayed higher OCR values, both at basal and maximal
respiration levels, compared to CD8+ T cells from T1/early
chronically-evolving patients (see Fig. 3e and the cell energy
phenotype plots in Supplementary Fig. 4c).
Evidence that this difference in glycolytic and mitochondrial
efficiency was not merely due to a lack of T cell activation was
provided by the increased cytokine production detected in HCV
peptide-stimulated compared to unstimulated cells (Supplemen-
tary Fig. 4e). Multiple lines of evidence also indicate that the
observed metabolic differences cannot be simply ascribed to
different frequencies of virus-specific CD8+ T cells within the
total CD8+ population or to an insufficient sensitivity of the
Seahorse analysis at the low HCV-specific CD8+ T cell
frequencies commonly found in HCV infected patients. In fact,
a similar difference in metabolic profiles between early self-
limited and chronically evolving acute infections was observed
when Seahorse analysis was performed in patients with different
disease outcomes but comparable numbers of IFN-γ producing
CD8+ T cells following HCV peptide stimulation (e.g., patient
# 1 vs. # 7 in Supplementary Fig. 5). Moreover, when similar
frequencies of IFN-γ producing CD8+ T cells were detected after
overnight stimulation of individual patients lymphocyte samples
with control and HCV-specific peptides, a better metabolic
performance was again detected in control compared to HCV
peptide-stimulated cells (e.g., patient #1 in Supplementary Fig. 5).
Finally, when tested with graded frequencies of FLU matrix
58-66-specific CD8+ T cells, Seahorse sensitivity appeared to be
sufficient to detect metabolic differences down to frequencies
lower than 0.5% FLU-specific T cells with respect to total CD8+
Fig. 1 Gene-expression profiling of virus-specific CD8+ T cells in HCV infection. a Principal-component analysis (PCA) of 4766 differentially expressed
genes (DEGs) identified by ANOVA (q-value≤ 0.05) in HCV-specific CD8+ T cells from patients with acute (n= 13), chronic (n= 7) and resolved (n= 4)
HCV infections, as well as FLU-specific CD8+ T cells from healthy controls (n= 5). Data were normalized with the quantile method and filtered for probes
detected in at least two-third of replicates for each condition. b Hierarchical-clustering representation of the 4766 DEGs. Data were median-normalized
before clustering and expressed as single patient profiling. In red upregulated and in blue downregulated genes. c Transcriptome profiles of HCV-specific
CD8+ T cells from chronically evolving and self-limited acute patients were compared by topological analysis at two different time-points (time of
diagnosis/T1 and several months later/T2). Twenty-nine and 277 pathways were significantly dysregulated (Benjamini-Hochberg corrected q-value≤
0.05) at the T1/early and T2/late time-points, respectively. Venn-diagram distribution of pathways identified as dysregulated by comparative topological
analysis of acute chronically-evolving vs. self-limited and chronic vs. resolved patients. The 15 pathways found to be significantly dysregulated in both
comparisons, but with a largely predominant trend toward upregulation (red) at T1/early and the opposite trend (blue) at T2/late, are listed in the bottom
panel; these include genes related to TCR signaling, DNA damage response and metabolism at the T1 comparison (each column shows the enrichment in
upregulated or downregulated genes in each pathway derived from the calculation of the median gene expression fold change in the comparison of
chronically evolving vs. self-limited–T1/early–and of late chronic vs. spontaneously resolved patients–T2/late). d List of the 14 T1/early-specific
dysregulated pathways, half of which are upregulated (red), while the remaining half is downregulated (blue). e Heat-map of differentially expressed genes
derived from GSEA (Molecular Signature Database, C2 canonical pathways and C5 gene ontology sets) at T1/early time-point, related to cell cycle, DNA
damage/DNA repair, cell signaling, mitochondrion and metabolism. Upregulated genes in red; downregulated genes in blue.
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Fig. 2 Glucose metabolism is impaired in HCV-specific CD8+ T cells from chronically evolving acute patients. a Representative examples of virus-
specific CD8+ T cells stained with HLA-A2+ dextramers ex vivo after overnight anti-CD3/anti-CD28 stimulation. Glucose uptake (b), measured by the
incorporation of the glucose analog 2-NBDG (MFI), and Glut1 expression levels (c) in virus-specific CD8+ T cells from T1/early HCV patients and healthy
controls stimulated as in a. Data are presented as median fluorescence intensity (MFI) values; median values are indicated by horizontal lines. Different
numbers of patients (represented by individual dots) were tested in each assay depending on dextramer-positive cell frequencies. b–c Differences between
multiple groups were evaluated with the non-parametric Kruskal-Wallis test; p-values were corrected for pairwise multiple comparisons with the Dunn’s
test. d metabolic flux profiling of purified CD8+ T cells from 6 T1/early chronically-evolving (acute) patients. Cells were stimulated overnight with either
HCV-NS3 (red) or control (FLU-specific, CMV-specific and EBV-specific) peptides (blue), or were not stimulated (green). The extracellular acidification
rate (ECAR) was measured in real-time ex vivo before (basal level) and after oligomycin treatment in order to determine the maximum glycolytic capacity
(MGC) and glycolytic reserve (difference between MGC and baseline ECAR) (see Methods section for details on Seahorse analysis). e Metabolic flux
profiling of purified CD8+ T cells from T1/early self-limited (acute) patients (n= 4) stimulated overnight as in d. ECAR, maximum glycolytic capacity and
glycolytic reserve were measured as in d. In d and e, ECAR values are given as the mean ± SD in the left-side and are presented as box-and-whisker plots
(with median and 5–95 percentile) in the right-side. d–e Statistical analysis was performed with the Friedman test to compare different stimuli; p-values
have been corrected for pair-wise multiple comparisons with the Conover’s test.
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T cells, which are comparable to, or even lower than, the
frequencies typically found in our acute HCV patients cohorts
(data not shown).
p53 drives early metabolic dysregulation in HCV-specific
CD8+ T cells. We then sought to elucidate the mechanisms
responsible for glycolytic impairment and the functionally inef-
fective transcriptional upregulation of OXPHOS genes. To this
end, we extracted a list of candidate regulatory genes (i.e., genes
upregulated in at least five of the eight functional categories
reported in Supplementary Fig. 2; see also the T1 sheets in Sup-
plementary Data 2) and performed a mutual interaction rela-
tionship analysis. As shown by the interaction map in Fig. 4a, p53
(also known as TP53), a known negative regulator of glycolysis
and an enhancer of OXPHOS30,31, was central to this network of
dysregulated genes. p53 upregulation, as well as enhanced
expression of its phospho-activated (p-Ser15) form in HCV-
specific CD8+ T cells from T1/early chronic compared to T1/
early self-limited patients were confirmed at the protein level
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(Fig. 4b, c). The Ataxia Telangiectasia Mutated (ATM) kinase, an
upstream regulator of p5332,33, was also upregulated in T1/early
chronically evolving patients (Supplementary Data 1 and 2) and
the phospho-activated (p-Ser1981) ATM protein was significantly
increased in CD8+ T cells from T1/early chronic compared to
T1/early self-limited HCV patients (Fig. 4d). ATM is responsible
for the AMP-activated protein kinase (AMPK)-dependent acti-
vation of the stress-sensor MAPK p38a34,35. Interestingly, p38a
(also known as MAPK14) and the AMPK subunits PRKAA1,
PRKAB1 and PRKAG1 were also upregulated at the transcrip-
tional level (Supplementary Data 1 and 2) and increased levels of
the phospho-activated (p-Thr180) form of p38a were detected in
CD8+ T cells from T1/early chronically evolving HCV patients
(Fig. 4e).
ATM is activated by DNA damage, ROS overproduction and
oxidative stress36,37. Notably, treatment with the ROS scavenger
resveratrol38,39 resulted in a reduction of mitochondrial reactive
oxygen species, which was accompanied by a significant decrease
of phospho-ATM and a smaller reduction of phosho-p53 and
phospho-p38a (Fig. 5a). Similar results were obtained with the
antioxidant N-acetyl-L-cysteine (NAC) in a smaller cohort of
patients (data not shown). Conversely, no significant phospho-
ATM decrease was observed when resveratrol was applied
to CD8+ T cells from T1/early chronically-evolving patients
stimulated with control viral peptides (Supplementary Fig. 6a).
To further probe the signal transduction network operating in
T1/early-exhausted HCV-specific CD8+ T cells, we assessed the
effect of different chemical inhibitors targeting ATM, p53,
AMPK, and p38 on the metabolic profile and anti-viral function
of CD8+ T cells (see Methods section for details). ATM, p53, and
p38a blockade strongly increased GLUT1 expression and glucose
uptake capacity, whereas a smaller effect was elicited by AMPK
inhibition (Fig. 5b, c). Treatment with ATM, p53 and p38a
inhibitors also reduced PD-1 levels (Fig. 5d), suggesting that PD-1
expression can be at least partially modified at an early stage of
chronically evolving infection.
Interestingly, treatment with specific transducer inhibitors
also enhanced the antiviral capacity of HCV-specific CD8+
T cells from T1/early chronically evolving patients, as revealed
by the increased cytokine (IFN-γ, TNF-α, and IL-2) production
observed in both ex vivo (Fig. 5e) and post 10-day culture
(Fig. 5f). Instead, only a modest effect was induced by the
same inhibitors on FLU-stimulated, CMV-stimulated, or EBV
peptide-stimulated PBMC from T1/early chronically-evolving
patients (Supplementary Fig. 6b–e), as well as on NS3-HCV-
peptide-stimulated PBMC from T1/early patients with an acute
self-limited infection (Supplementary Fig. 7a, b). The above data
suggest that transducer inhibitors may represent promising
therapeutic tools to prevent progression and worsening of T cell
exhaustion.
Global transcriptional repression in T2/late HCV-specific
CD8+ T cells. To delineate the dysfunctional features of the
T2/late-chronic stage, we focused on the comparison between
HCV-specific CD8+ T cells from established chronic and late-
resolved patients. Most functional categories identified as dysre-
gulated in the T2/late stage by GSEA were downregulated, as
indicated by the negative Normalized Enrichment Score (NES)
values reported in Supplementary Data 2 (T2 sheets). Gene sets
significantly enriched at both T1/early and T2/late time-points
but oppositely regulated (i.e., upregulated at T1 and down-
regulated at T2) are outlined in Fig. 6a. T2/late-downregulated
gene sets include genes coding for genome safeguard, cell cycle/
checkpoint regulation, proteasomal degradation, mitochondrial
metabolism and OXPHOS components, as well as multiple signal
transducers acting downstream to TCR activation (Fig. 6a, b and
T2 Sheets in Supplementary Data 2). qPCR validation, applied to
the comparison of T2/late-chronic vs. resolved HCV patients and
healthy FLU controls, confirmed the expression trends revealed
by microarray analysis for a subset of T cell effector (e.g., ZAP70,
LAT, AKT1, and Tbet, also known asTBX21) and regulator genes
(e.g., ADCY4, BATF), whereas basal expression levels or a weak
upregulation were observed for the TCR regulators PD-1 and
CTLA-4, respectively (Supplementary Fig. 8)4,40,41. To further
investigate these signaling pathways at the protein level, all
patient categories were analyzed longitudinally (see Supplemen-
tary Fig. 9). Phosphorylated-ATM levels did not change in CD8+
T cells from T2/late chronic patients (Supplementary Fig. 9a),
whereas total p53 levels increased in T2/late chronic compared to
T2/late resolved patients and healthy controls (Supplementary
Fig. 9b, on the left). In contrast, we did not observe any significant
increase in Ser15 phosphorylated p53 levels (Supplementary
Fig. 9b, lower graph), as it may be expected considering that
phosphorylation at this position is mediated by the ATM, ATR,
and AMPK kinases, all of which are transcriptionally down-
regulated in T2/late chronic patients (see T2 sheets in Supple-
mentary Data 2). However, since p53 can be phosphorylated by
other protein kinases at different sites42—e.g., Ser46 phosphor-
ylation by p38, whose phosphorylated form did not change
appreciably between T2/late chronic and resolved patients (Sup-
plementary Fig. 9c)—we cannot conclude that p53-dependent
signaling is necessarily depressed.
Fig. 3 Mitochondrial metabolism is impaired in HCV-specific CD8+ T cells from chronically evolving acute patients. a Percentage of mitochondrial
depolarized virus-specific CD8+ T cells, detected with HLA-A2+ dextramers ex vivo after overnight anti-CD3/anti-CD28 stimulation, by staining with the
mitochondrial membrane potential (MMP) sensitive dye JC-1 (see Methods section for details). Dextramer-positive virus-specific depolarized cells were
quantified by subtracting the percentage of FL1high/FL2low cells (JC-1 staining) detected in the unstimulated samples from the percentage of the
corresponding cellular subsets detected in the stimulated samples, as previously reported23. b Mitochondrial superoxide levels determined ex vivo as in a
with the MitoSOX Red dye. c Cytoplasmic reactive oxygen species (ROS) determined ex vivo, as in a, with the superoxide-specific dye DHE and the
intracellular H2O2 specific dye H2DCFDA are shown on the left and on the right, respectively. a–c Data are presented as median fluorescence intensity
(MFI) values; median values are indicated by horizontal lines. Different numbers of patients (represented by individual dots) were tested in each assay
depending on dextramer-positive cell frequencies. a–c Differences between multiple groups were evaluated with the non-parametric Kruskal-Wallis test; p-
values were corrected for pairwise multiple comparisons with the Dunn’s test. d Oxygen consumption rate (OCR) data determined on the same samples
(n= 6 T1/early chronically evolving acute patients) utilized for ECAR analysis (see Fig. 2d) before (basal level) and after addition of the mitochondrial
stressors oligomycin, FCCP and rotenone/antimycin A, which were used to calculate ATP production, maximal respiration capacity, spare respiratory
capacity, coupling efficiency and proton leak, as indicated. e, OCR, ATP production, maximal respiration capacity and spare respiratory capacity were
determined on the same samples (n= 4 T1/early self-limited acute patients) utilized for ECAR analysis in Fig. 2e, and were calculated as in d. In d and e,
OCR values are given as the mean ± SD in the left-side and are presented as box-and-whisker plots (with median and 5–95 percentile) in the right-side.
d–e Statistical analysis was performed with the Friedman test to compare different stimuli; p-values have been corrected for pair-wise multiple
comparisons with the Conover’s test.
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Furthermore, a significant reduction of mitochondrial
polarization (Fig. 6c, left panel) and a marked accumulation
of proteasome-undegraded aggregated proteins (Fig. 6c, right
panel) were detected ex vivo in HCV-specific CD8+ T cells
from T2/late chronic compared to T2/late resolved patients
and healthy controls. Further investigation of cellular metabo-
lism at the T1 and T2 time-points, revealed sustained glucose
uptake and GLUT1 expression levels in T2/late chronic patients
(Supplementary Fig. 10a), associated with elevated PD-1
protein expression (Supplementary Fig. 10b), dysfunctional
mitochondria and excess mitochondrial (but not cytoplasmic)
ROS levels (Supplementary Fig. 10c, d). Mitochondrial defects
were already evident in the T1/early acute phase of chronically
evolving infection (Supplementary Fig. 10c). Proteasomal
dysfunction, instead, was not detectable in the same group
of T1/early chronically evolving patients at the T1 time-point
b
Cellular response to DNA damage stimulus
Cellular response to stress
Mitochondrial DNA metabolic process
Regulation of cell cycle
Cellular senescence
Cellular response to glucose starvation
Negative regulation of transcription from 
RNA polymerase II promoter
c
p5
3 
M
FI
Total p53
Unstimulated 
samples
a
100
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
Ac
ute
 HC
V c
hr.
 ev
ol.
Ac
ute
 HC
V s
elf-
lim
.
FL
U h
ea
lth
y
200
300
400
500 0.003
0.003
Anti-CD3/CD28 
stimulated 
samples
Ratio stimulated 
vs unstimulated
0.5
1.0
1.5
2.0
2.5
0.007
ns
1.0
1.5
2.0 0.002
0.011
0.8
1.6
2.4
0.003
0.007
100
200
300
400
0.011
0.002
p-
p3
8 
M
FI
400
600
800
1000
1200 0.019
<0.001
p-
p5
3 
M
FI
p-
AT
M
 M
FI
1000
2000
3000
4000 0.013
0.062
100
200
300
400 0.001
0.001
0
500
1000
1500
2000
0.003
0.016
2000
4000
6000
<0.001
0.011
pATM
p-p53
p-p38
d
e
p53
p-ATM p-ATM
p-p53 p-p53
p-p38 p-p38
Fo
ld
 c
ha
ng
e 
st
im
ul
at
ed
/u
ns
tim
ul
at
ed
de
xt
ra
m
er
+ 
CD
8+
 T
 c
el
ls 
(M
FI)
Fo
ld
 c
ha
ng
e 
st
im
ul
at
ed
/u
ns
tim
ul
at
ed
de
xt
ra
m
er
+ 
CD
8+
 T
 c
el
ls 
(M
FI)
Fo
ld
 c
ha
ng
e 
st
im
ul
at
ed
/u
ns
tim
ul
at
ed
de
xt
ra
m
er
+ 
CD
8+
 T
 c
el
ls 
(M
FI)
102 103 104
102 103 104
0 104 105
102 103 104
0 104 105
102101 103 104102101 103 104
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-14137-7
8 NATURE COMMUNICATIONS |          (2020) 11:604 | https://doi.org/10.1038/s41467-019-14137-7 | www.nature.com/naturecommunications
(Supplementary Fig. 10e, red circles), in accordance with
transcriptome data indicating a strong upregulation of protea-
somal subunits genes at this stage of infection (Fig. 6a,
Supplementary Fig. 2 and T1 sheets in Supplementary Data 2).
Taken together these results indicate that mitochondrial and
proteasomal functions, despite their divergent behavior in the
early phase of infection (T1), are profoundly impaired in HCV-
specific CD8+ T cells from T2/ chronic patients.
Epigenetic repressive mechanisms in fully exhausted HCV-
specific CD8+ T cells. To explain the massive transcriptional
downregulation that accompanies and likely contributes to the
chronic outcome of HCV infection, we hypothesized the invol-
vement of chromatin-based silencing mechanisms. To test this
hypothesis, we used the EpiFactors database of epigenetic reg-
ulators43 as a reference to interrogate the T1/early and the T2/late
transcriptome datasets for dysregulated chromatin modifiers.
Genes comprised in the histone H2A/H2B deubiquitination
(DUB) and the histone methyltransferases (HMT) complex
denominations were consistently upregulated in chronic patients
compared to resolvers and healthy controls (Fig. 6d). We focused
on the HMTs G9a (also known as EHMT2), which methylates
lysine 9 of histone 3, and EZH2, which methylates lysine 27 of
histone 3, because of their repressive effects44–46. As shown in
Fig. 6e, significantly higher levels of H3 K9 di-methylation were
detected in HCV-specific CD8+ T cells from T2/late chronic
patients compared to T2/late resolvers and healthy controls.
Interestingly, under the same short-term culture conditions, H3
K9 di-acetylation, which marks relaxed, transcriptionally active
chromatin and is mutually exclusive with the repressive H3
K27me3 mark, displayed an opposite behavior, being significantly
more represented in CD8+ T cells from T2/late resolvers and
healthy controls compared to T2/late chronic patients (Fig. 6e).
Interestingly, repressive chromatin marks were already detectable
in the early phase (T1) of chronically evolving infections com-
pared to healthy controls (Supplementary Fig. 10f).
To further investigate the relationship between repressive
histone methylation and T cell functionality, we used four
different inhibitors to selectively target the T2/late-chronic phase
upregulated HMTs G9a (UNC0638 and BIX01294) and EZH2
(GSK126 and EPZ005687). Treatment with HMT inhibitors
increased GLUT1 levels and glucose import in HCV peptide-
stimulated PBMC from T2/late chronic patients (Fig. 7a, b). HMT
inhibitors also reduced PD-1 expression levels in T1/early but less
efficiently in T2/late HCV-specific CD8+ T cells (Fig. 7c).
Moreover, the number of single-positive and double-positive
IFN-γ/TNF-α-producing CD8+ T cells was markedly increased
by HMT inhibitor treatment upon peptide stimulation both
ex vivo (Fig. 7d–f) and after short-term culture (Fig. 7g–j and
Supplementary Fig. 11), with a particularly significant effect
on T2/late-chronic CD8+ T cells. As shown by the increased
frequency of HCV dextramer-positive CD8+ T cells upon
stimulation with HLA-A2 restricted peptides, HMT inhibitors,
which caused a reduction of H3 K9 di-methylation detectable
both ex vivo and after 10 days of culture in CD8+ T cells from
T2/late chronic patients (Fig. 7k), also improved the expansion
capacity of these late-exhausted cells (Supplementary Fig. 12).
This effect was appreciably more potent on T2/late exhausted
HCV-specific CD8+ T cells than on fully functional HCV-
specific CD8+ T cells from T2/late resolved patients (Supple-
mentary Fig. 13a) and functional CD8+ T cells of different virus-
specificities (FLU, CMV, EBV in Supplementary Fig. 13b).
Given the persistent upregulation of p53 throughout the
different phases of HCV infection, the effect of p53 inhibition on
cytokine production, glucose uptake and PD-1 expression levels
was also tested on T2/late chronic HCV-specific CD8+ T cells. As
in the case of HMT inhibitors, all the tested parameters were
positively affected by p53 blockade, with an increase in glucose
uptake, a decline of PD-1 levels and an increased cytokine
production (Fig. 7b, c, d–j, blue dots and Supplementary Fig. 11),
thus pointing again to a key role of p53 as a central regulator of T
cell exhaustion.
CD8+ T cell function in DAA-treated chronic hepatitis C
patients. We finally asked if and to what extent HCV replication
blockade and antigen decline may affect the metabolic and epi-
genetic dysregulation marks documented in CD8+ T cells from
T2/late chronic patients. To address this question, we investigated
glucose import, mitochondrial depolarization, PD-1 expression,
proteasomal activity and repressive histone methylation in CD8+
T cells from T2/late chronic patients treated with direct acting
antivirals (DAA; see Supplementary Data 3a, b). After HCV
clearance, glucose import was significantly reduced (Fig. 8a), even
though it did not reach the levels found in spontaneous resolvers.
Mitochondrial depolarization declined in T2/late HCV-specific
CD8+ T cells from some but not all patients at the end-of-
therapy (EOT) (Fig. 8a), with a behavior similar to what we
observed in the case of PD-1 expression levels (Fig. 8a). This
contrasts with the recovery of proteasomal function revealed by
the significant reduction in unfolded protein aggregates (Fig. 8a).
Variable results were obtained with the repressive H3K9me2
mark, which at EOT remained higher than in spontaneous T2/
late resolvers and healthy controls (Fig. 8a).
We also compared the effect of histone methylation and p53
inhibition on the antiviral activity of CD8+ T cells from T2/late
chronic patients before and after DAA therapy (see Supplemen-
tary Data 3a, b). Treatment with p53 and HMTs inhibitors
(pifithrin-alfa for p53, GSK126 and EPZ005687 for EZH2,
Fig. 4 ATM and p53 pathways are activated in T1/early HCV-specific CD8+ T cells. a Interaction network of genes involved in at least five of the eight
dysregulated processes identified by GSEA (outlined in Supplementary Fig. 2). The network was generated using STRING v. 10.5. Node colors refer to
enriched pathways associated with the proteins represented in the network. Line thickness indicates the degree of confidence prediction of the interactions.
b Intracellular staining for total p53 of dextramer positive virus-specific CD8+ T cells from patients in the acute phase of HCV infection (chronically
evolving T1/early n= 19 and HCV self-limited T1/early n= 14) or from healthy controls (n= 14), performed after overnight stimulation with anti-CD3/anti-
CD28 (ex vivo staining). c Intracellular staining for phospho-p53 (Ser15) of dextramer positive virus-specific CD8+ T cells from PBMCs derived from
patients in the acute phase of HCV infection or from healthy controls was performed with no stimulation and after overnight anti-CD3/anti-CD28 stimuli
(left and middle panels, respectively). The plot on the right represents the ratio between anti-CD3/anti-CD28 stimulated and unstimulated virus-specific
CD8+ T cells. d Intracellular staining for phospho-ATM (Ser1981) of dextramer positive virus-specific CD8+ T cells as in c. e Phospho-p38 (Thr180)
intracellular staining of dextramer positive virus-specific CD8+ T cells as in c. Data in panels from b to e are presented as median fluorescence intensity
(MFI), with median values indicated by horizontal lines. Different numbers of patients (represented by individual dots) were tested in each assay
depending on dextramer-positive cell frequencies. Representative overlay histograms are shown next to each plot in panels from b to e. All data were
analyzed with the Kolmogorov-Smirnov test. Differences between multiple groups were evaluated with the nonparametric Kruskal-Wallis test; p-values
were corrected for pairwise multiple comparisons with the Dunn’s test (JASP software).
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UNC0638 and BIX01294 for G9a) markedly increased the
frequency of single-positive and double-positive IFNγ/TNFα-
producing CD8+ T cells upon peptide stimulation both ex vivo
(Fig. 8b) and after 10 days of culture (Fig. 8c). Conversely, the
same set of inhibitors had a modest effect when supplied after
therapy withdrawal (EOT), with a significant increase of anti-viral
cytokine production only observed after 10 days of culture but
not under ex vivo conditions (Fig. 8b, c and Supplementary
Fig. 11).
Discussion
Knowledge of the molecular and cellular features of the T cell
responses associated with self-limited compared to persistent viral
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infections has greatly advanced in recent years1,6,12,13,17,19.
However, our understanding of the regulatory mechanisms
responsible for these different outcomes remains largely incom-
plete, especially in the case of human infections13,25. Here, we
combined transcriptome profiling, cell metabolic analyses and
selective targeting of newly identified dysregulated pathways, to
examine and compare the functional features of HCV-specific
CD8+ T cells at different time-points along the transition from
acute hepatitis to a resolved (memory T cell generation) or a
chronic (exhausted T cells) outcome of infection. Short-term
culture conditions in the presence of either HCV-specific peptides
or anti-CD23/anti-CD28 antibodies were set-up in order to cir-
cumvent the strong limitations inherent to the extremely low
frequency of HCV-specific CD8+ T cells. These conditions,
which differ from the much more prolonged stimulation com-
monly applied in human studies of virus-specific CD8+ T cells,
were also aimed to limit possible artifactual metabolic alterations
associated with long-term culture and in vitro expansion.
We found that a predominantly upregulated gene expression
profile marks HCV-specific CD8+ T cells committed to
exhaustion at early times of infection, in patients who will ulti-
mately develop chronic hepatitis C. However, this extensive
upregulation, which involves DNA damage stress responses and
multiple intracellular signaling pathways, including T cell recep-
tor downstream effectors, the CD28-dependent PI3K/Akt ana-
bolic pathway and several mitochondrial components, does not
lead to an improved antiviral function but rather translates into a
deep functional impairment at both the energetic and metabolic
level. Such a dissociation between transcriptional and functional/
metabolic outputs was particularly evident for OXPHOS
impairment, which was associated with an altered MT membrane
potential and ROS accumulation.
While OXPHOS was transcriptionally upregulated but func-
tionally depressed, glucose utilization and related glycolytic
functions were downregulated at both the gene expression and the
functional level in T1/early chronic CD8+ T cells committed to
exhaustion. Reduced glycolytic activity and inefficient OXPHOS
have recently been reported for exhausted CD8+ T cells in the
mouse LCMV model of persistent viral infection25. Thus, a
common metabolic alteration with divergent transcriptional and
functional responses likely reflecting a failed compensatory
attempt, is shared by exhausted CD8+ T cells across different
species. This profound metabolic derangement is expected to
impact on the capacity of T cells to express efficient anti-viral
effector functions18–20 and to generate protective memory21,22
suggesting that its selective targeting may provide new avenues for
novel rational therapeutic interventions.
p53 is known to negatively affect glycolysis and to promote
OXPHOS, thus resulting in ROS production30,31. In the case of
prolonged stimulation and/or irreparable DNA damage, p53
activation induces a sustained pro-oxidative state that may result
in the repression of mitochondrial biogenesis and mitochondrial
dysfunction30,31. Different lines of evidence point to p53 as a
highly plausible driver of the initial transition to the exhaustion
program in HCV infected patients. p53, which was found to be
upregulated at both the transcript and protein level (including its
phospho-activated form) in HCV-specific CD8+ T cells from
early-chronic patients, emerged as a central hub in the network
of regulatory genes retrieved from interaction analysis of our
transcriptome data. Indeed, p53 is modulated transcriptionally
by type I interferons (IFN)31 that are actively engaged in the
initial phase of HCV infection47,48, as also indicated by the
multiple IFN-stimulated genes we found to be upregulated in T1/
early-exhausted HCV-specific CD8+ T cells. Notably, the DNA
damage sensor kinase ATM, which activates p53 by Ser15
phosphorylation, was also upregulated at the transcript and
protein level in T1/early exhaustion-committed CD8+ T cells.
Despite the present lack of direct supporting evidence, it is con-
ceivable to imagine that the DNA replication stress caused by
elevated viral loads and the resulting persistent TCR signaling are
responsible for ATM upregulation. Accordingly, transcripts
coding for T cell receptor downstream effectors, as well as cell
cycle machinery and DNA replication components were also
found to be upregulated in T1/early-exhausted HCV-specific
CD8+ T cells.
In addition to a role in the cellular metabolic homeostasis, p53
is primarily known to play a general role in promoting apoptosis
and permanently blocking cell proliferation under various stress
conditions30. In our study, only a very limited proportion of
p53high HCV-specific CD8+ T cells from chronically evolving
acute patients were found to be positive for Caspase 9, which has
been reported to play a major role in apoptosis induction in the
acute phase of HCV infection49. Conversely, nearly half of the
p53high HCV-specific CD8+ T cells in our study expressed the
anti-apoptotic BCL2 regulator at high levels (data not shown),
thus suggesting that only a minor fraction of the p53-positive
HCV-specific CD8+ T cell population we used for our functional
analyses was actually undergoing apoptosis. Moreover, the actual
amount of pre-apoptotic cells might have been further lowered by
overnight stimulation of dextramer-positive CD8 T cells with
anti-CD3 and anti-CD28 antibodies, a treatment that is expected
to drive apoptosis-committed T cells toward apoptotic death50,51.
Altogether, the above data strongly suggest that the p53 increase
observed in chronically evolving HCV patients is related to less
conventional (e.g., metabolic adaptation) p53-mediated functions,
rather than to apoptosis promotion.
Importantly, a key role of p53 in the initial triggering of
exhaustion is also supported by the restoration of both metabolic
Fig. 5 Blocking dysregulated intracellular signaling pathways can reverse early metabolic and functional CD8+ T cell defects. a PBMC from T1/early
chronically-evolving patients were stimulated overnight with HCV-NS3 peptides in the presence or absence of the ROS scavenger resveratrol38,39 (treated
vs. untreated) and then stained with MitoSOX Red to assess mitochondrial superoxide content and with anti-phospho-ATM (Ser1981), phospho-p38
(Thr180), and phospho-p53 (Ser15) antibodies. Bars represent mean fold-change values+ SEM derived from 6 patients. Representative overlay histograms
are illustrated on the right. b PBMCs from T1/early chronically-evolving patients were stimulated for 40 h with HCV-NS3 peptides in the presence or
absence of specific ATM (KU-55933), p53 (Pifithrin-α), AMPK (Dorsomorphin), and p38a (SB203580) inhibitors, followed by flow cytometry
determination of GLUT-1 expression levels. Representative dot plots are illustrated on the right. Glucose uptake studied via incorporation of the glucose
analog 2-NBDG (c) and PD-1 expression (d) have been measured as in b. e IFN-γ, TNF-α, and IL2 production by CD8+ T cells cultured as in b. Data are
presented as the ratio between the percentage of cytokine positive CD8+ T cells detected in inhibitor-treated vs. untreated cultures (fold-change). f IFN-γ,
TNF-α, IL2 single positive, as well as double-positive IFN-γ+/TNF-α+CD8+ T cells generated in short-term T cell lines upon 10-days stimulation with
HCV-NS3 peptides in the presence or absence of the inhibitors specified in the legend to panel b. Data shown in all panels are presented as fold-change of
treated vs. untreated CD8+ T cells. Horizontal lines in panels b to f represent median values; data were analyzed statistically with the Wilcoxon signed-
rank test; NS= not significant.
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and antiviral functions, and the concomitant reduction of PD-1
levels, elicited by treatment with a specific p53 inhibitor. A link
between p53 and immune-checkpoint regulators has recently
been described in human cancer cells, which respond to geno-
toxic stress and DNA damage via p53-dependent upregulation of
PD-1 and its PD-L1 ligand52. The effect of p53 inhibition on PD-1
expression levels we observed in T1/early exhaustion-committed
HCV-specific CD8+ T cells, thus provides further support to the
existence of a regulatory link between p53 and PD-1, which may
play an as yet unappreciated role in T cell exhaustion. The
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group of pathways. b Heat-maps comparing the expression profiles of leading genes belonging to the DNA repair/damage response, metabolism and cell
signaling pathways in chronic and resolved infections (see also the T2 sheets in Supplementary Data 2). c Mitochondrial (left panel, JC-1 staining) and
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specific CD8+ T cells from T2/late chronic and T2/late resolved HCV patients or healthy controls. PBMC were stimulated overnight with anti-CD3/CD28
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Differences between multiple groups in panels c and e were evaluated with the non-parametric Kruskal-Wallis test; p-values were corrected for pairwise
multiple comparisons with the Dunn’s test.
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Fig. 7 HMT and p53 inhibitors improve anti-viral and metabolic functions of exhausted HCV-specific CD8+ T cells. PBMC from chronically evolving
(T1/early) or chronic (T2/late) HCV patients were stimulated for 40 h with HCV-NS3 peptides in the presence or absence of the EZH2 inhibitors GSK126
(GSK) and EPZ005687 (EPZ) (red dots), of the EHMT2/G9a inhibitors UNC0638 (UNC) and BIX01294 (BIX) (green dots), and of the p53 inhibitor
pifithrin-alfa (p53) (blue dots). HCV-stimulated CD8+ T cells were then tested in flow cytometry for GLUT-1 levels (a), glucose uptake (b), PD-1
expression (c), IFN-γ (d), TNF-α (e), and IL2 (f) production. g–j PBMC from chronically evolving (T1/early) or chronic (T2/late) HCV patients were
stimulated for 10 days with HCV-NS3 peptides in the presence or absence of the inhibitors specified in a and CD8+ T cells were then tested for IFN-γ,
TNF-α, IL2, and IFN-γ plus TNF-α production as indicated. Data are presented as the ratio (fold-change) between positive CD8+ T cells detected in treated
vs. untreated cultures from individual patients. Statistical analysis was performed with the Wilcoxon signed-rank test; horizontal lines represent median
values. k Reduction of the repressive H3K9me2 histone mark was assessed by flow cytometry on CD8+ T cells from T2/late chronic HCV patients
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relevance of our model to other T cell exhaustion-associated
pathologies, including cancer, is further corroborated by the
increased effector function and enhanced glycolytic commitment
exhibited by T cells derived from p53 knock-out mice53. In the
same model, adoptive transfer of p53 knock-out T cells has been
shown to improve the control of a subcutaneously established
murine melanoma, thus highlighting a key role of p53 in mod-
ulating tumor-reactive T-cell responses with a potential transla-
tional significance in adoptive T-cell therapy53.
ATM downstream targets upregulated in T1/early chronic
CD8+ T cells also include AMPK (PRKAA1, PRKAB1, and
PRKAG1 subunits) and the MAPK/stress sensor kinase p38a
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(also known as MAPK14). The latter has been shown to be
involved in T cell senescence with markedly negative effects on
telomerase activity, cell proliferation and expression of key
components of the TCR signalosome34,35. Accordingly, we found
that T2/late exhausted HCV-specific CD8+ T cells display a
profoundly reduced expression of intracellular transducers
downstream to TCR activation, including the proximal kinases
ZAP70 and CD3zeta chain (also known as CD247), AKT1, and
PLCG1. Pharmacological inhibition of ATM, AMPK, and p38a
rescued to varying extents the metabolic and antiviral activity
defects associated to early exhaustion of T1/ chronically-evolving
CD8+ T cells. Altogether, our data suggest that ATM, p53, and
p38a cooperate in the establishment of a pre-senescent,
exhaustion-oriented state.
Although we do not formally delineate a biochemical cascade
leading to metabolic dysregulation in T1/early exhausted HCV-
specific CD8+ T cells, ROS accumulation, resulting from
OXPHOS derangement and impaired detoxification, links mito-
chondrial dysfunction to ATM and p53 activation; in line with
this, antioxidant treatment led to a marked decline of phospho-
ATM levels.
Contrasting with the predominant upregulation that char-
acterizes exhaustion-committed CD8+ T cells in the T1/early
phase of HCV infection, a massive transcriptional downregulation
was observed in T2/late-exhausted CD8+ T cells. This involved a
variety of genes and pathways related to core cellular processes
such as cell cycle checkpoints, chromosome/telomere maintenance,
transcription and mitochondrial function and to intracellular sig-
naling downstream to TCR activation (see Supplementary Data 2
for a complete list of T2-downregulated genes). Despite progres-
sion towards a widespread downregulation, a number of genes
were found to be upregulated in T2/late-exhausted CD8+ T cells
(T2 sheets in Supplementary Data 1), including genes coding for
negative regulators of TCR signaling (e.g., adenylate cyclase 1 and
4, also known as ADCY1 and 4; NFAT1 also known as NFATC2;
and NFAT2 also known as NFATC1)40,54, mRNA translation (e.g.,
the interferon-inducible protein kinase PKR also known as
EIF2AK2; the GCN2 kinase also known as EIF2AK4; and 4EBP1
also known as EIF4EBP1)55, and chromatin architectural compo-
nents (e.g., the high-mobility group protein HMGA1)56.
Chromatin remodeling via histone modification has recently
been implicated in various cell fate transitions associated with T
cell development57–60. The PRC2 repressive complex and its
catalytic subunit, the H3K27 histone methyltransferase EZH2,
have been shown to regulate terminal effector (and memory)
CD8+ T cell differentiation57–61, whereas the H3K9 methyl-
transferase G9a has been reported to promote the expression of
inhibitory receptors during T cell exhaustion in chronic LCMV
infection and to repress type I cytokine gene expression in Th2
cells62,63. Through EpiFactors database investigation, we found that
both HMTs and additional PRC2 complex components (e.g., EED,
Suz12, RBBP4, and Jarid2)61 are upregulated in T2/late-exhausted
HCV-specific CD8+ T cells compared to the same cells from T2/
late resolved patients. Accordingly, we observed an increase in the
repressive H3K9me2 mark, accompanied by reduced levels of
the activating H3K9ac2 mark (mutually exclusive with the repres-
sive H3K27me3 modification) in T2/late exhausted HCV-specific
CD8+ T cells. Notably, EZH2 and G9a upregulation was already
apparent at the T1/early time-point. Whether this reflects an early
initiation of the repressive chromatin remodeling program or the
presence of a qualitatively different methylation landscape in the
two phases of the infection process remains to be determined.
Also lacking, is direct evidence on the actual trigger of histone
methylation-dependent silencing, although it is likely that, at least in
the case of EZH2, upregulation is driven by DNA damage and the
increased E2F1 activity associated with cell proliferation64.
A causative role of H3K9 and H3K27 methylation in the
modulation of CD8+ T cell exhaustion is strongly supported by
the significant restoration of metabolic and antiviral functions,
together with an improved expansion capacity, elicited by phar-
macological inhibition of the G9a and EZH2 histone methyl
transferases in T2/late-exhausted HCV-specific CD8+ T cells. A
similar functional recovery was observed upon p53 blockade and
it was paralleled by both an improved CD8+ T cell metabolic
capacity, including increased glucose uptake and GLUT1
expression levels, and a significant decrease of PD-1 expression.
Interestingly, EZH2 inhibition also positively affected GLUT1
expression but with a limited or no effect on PD-1. This suggests
the existence of only a partial overlap between the transcriptional
repression programs driven by the EZH2 and G9a HMTs
and p53.
Given the functional recovery results obtained with multiple,
rationally selected inhibitors, some of which are currently being
tested in oncology clinical trials65, it is conceivable to imagine
that knowledge generated in this study holds considerable
potential for translation into novel and more effective T cell
reconstitution strategies.
The contribution of HCV-specific T cells to virus clearance
promoted by DAA treatment is still a matter of debate66,67. The
prevalent view, however, based on studies performed in resolved
HCV infections, either spontaneously or after IFN-alpha ther-
apy68, and, more recently, in DAA-treated patients12 is that
resolution of HCV infection does not lead to a complete
recovery of the HCV-specific T cell function. Specifically, reso-
lution of infection in DAA treated patients does not appear to
be associated with the acquisition of a conventional memory
phenotype by HCV-specific CD8+ T cells. In fact, most virus-
specific T cells differentiate into a memory-like (or “exhausted
Fig. 8 Effect of DAA treatment and HMTs/p53 modulation on HCV-specific CD8+ T cells from chronic patients. a Glucose uptake (measured by the
incorporation of the glucose analog 2-NBDG), percentage of depolarized mitochondria (by staining with the mitochondrial membrane potential sensitive
dye JC-1), PD-1 expression, proteasomal function (by ProteoStat staining) and repressive H3K9me2 mark were assessed in virus-specific, dextramer-
stained CD8+ T cells from T2/late HCV patients (n= 9) at baseline and at EOT, from T2/late resolved patients and from healthy controls after overnight
anti-CD3/anti-CD28 stimulation (see Methods section for details). All data were analyzed with the Kolmogorov-Smirnov test, followed by Wilcoxon
matched-pairs signed rank test (paired for chronic patients at baseline vs. EOT). Conversely, differences between multiple patient groups were evaluated
with the non-parametric Kruskal-Wallis test; p-values were corrected for pairwise multiple comparisons, with the Dunn’s test. b PBMC from chronic HCV
patients (T2/late; n= 6) at baseline and at EOT were stimulated for 40 h with HCV-NS3 peptides in the presence or absence of the EZH2 inhibitors
GSK126 (GSK) and EPZ005687 (EPZ) (red dots), of the G9a inhibitors UNC0638 (UNC) and BIX01294 (BIX) (green dots), and of the p53 inhibitor
pifithrin-alfa (p53) (blue dots), followed by co-staining for IFN-γ, IL2, and TNFα (left). c PBMC from baseline and EOT of T2/late chronic HCV patients
(n= 11) were stimulated for 10 days with HCV-NS3 peptides as in b. Data in b and c are presented as the ratio (fold-change) between cytokine producing
CD8+ T cells detected in treated vs. untreated cultures from individual patients; statistical analysis was performed with the Wilcoxon signed-rank test;
horizontal lines represent median values.
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memory”) CD8+ T cell population (CD127+/TCF1+/BcL2+/
PD-1+) with an ability to produce anti-viral cytokines and to
proliferate greater than terminally exhausted (CD127-/PD-1hi)
CD8+ T cells but lower than that of real memory CD8+ T cells
(CD127+/PD-1-)12.
In keeping with the partial DAA mediated recovery highlighted
by some of the above studies, we did not observe a complete
correction of dysfunctional metabolic and repressive histone
methylation marks in virus-specific CD8+ T cells from T2/late
DAA-treated patients. Interestingly, we also observed a higher
efficacy of HMTs and p53 inhibitors when applied before the start
of DAA therapy (i.e., in the presence of a high viremia) rather
than after HCV clearance at DAA suspension.
Combined DAAs and HMTs/p53 inhibitors may thus be par-
ticularly valuable for the secondary treatment of HCV-positive
patients not properly responding to last-generation antivirals. Also
notable is the overlap (and co-enrichment) of the gene-sets found
to be dysregulated in the present study and those of conceptually
similar transcriptome profiling studies conducted in the LCMV
model of chronic infection69,70 (Supplementary Fig. 14a), in HIV
(progressors vs. controllers; see Supplementary Fig. 14b)41, in
HBV (Supplementary Fig. 14c)23 and in HCV (early chronically-
evolving patients) infections (Supplementary Fig. 14d)26. This
suggests that the HMTs/p53 inhibitors might also be effective in
other viral and non-viral chronic pathologies (including cancer)
sharing a T cell exhaustion phenotype.
Methods
Human subjects and samples. The following groups of patients (Supplementary
Data 3) were enrolled into the study at the Unit of Infectious Diseases and
Hepatology of the Azienda Ospedaliero-Universitaria of Parma, Italy:
84 T2/late treatment-naive patients with chronic active hepatitis C (aged 20–67
years; median 45 years); diagnosis was based on the finding of positive serum
HCV-RNA and alanine aminotransferase (ALT) elevation for at least 1 year;
20 T2/late chronic active hepatitis C genotype 1 patients were followed through
IFNα-free DAA therapy (Supplementary Data 3b).
85 T1/early patients with acute hepatitis C, 52 of them with chronic evolution of
infection (aged 18–73 years; median 41 years) and 33 with a self-limited
outcome (aged 23–70 years; median 40 years), with clinical, biochemical and
virological evidence of acute HCV infection (transaminase levels at least ten
times higher than the upper limit of the normal range, anti-HCV antibody, and
HCV-RNA positive);
26 T2/late subjects who spontaneously recovered from acute HCV infection
(aged 19–64 years; median 33 years), recruited 8 to 18 months after the peak of
ALT elevation;
28 healthy subjects (aged 23–54 years; median, 36 years), as controls.
All patients were negative for anti-hepatitis B virus, delta virus, human
immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) antibodies and for
other markers of viral or autoimmune hepatitis. No randomization was used to
determine patient groups, and during all experiments, investigators were not
blinded to the group allocation. The study was approved by the Government of the
Emilia-Romagna Region, Italy (protocol n. 1786/2012) and by the Ethical
Committee of the Azienda Ospedaliero-Universitaria of Parma, Italy, (protocol
n. 9787/2013 and protocol n. 9050/2017) and all subjects provided written,
informed consent.
Synthetic peptides, peptide-HLA class I dextramers, and antibodies. A total of
130, 15-mer overlapping peptides, corresponding to the entire sequence of the
HCV-NS3 protein of genotype 1 (Mimotopes, Victoria, Australia) were pooled into
a single mixture and used in functional validation experiments performed in HLA-
A2-negative patients. A pool of immunodominant peptides from CMV, EBV, and
FLU sequences of various HLA-class I and II restriction was used in HLA-A2-
negative patients as a control for other viral specificities. Peptides covering the
HLA-A2-restricted genotype-specific HCV epitopes corresponding to NS3 amino-
acids 1073–1081, 1406–1415, NS4 1992–2000, and NS5 2627–2635, and to the
influenza virus (FLU) matrix amino-acids 58–66 (Mimotopes, Victoria, Australia)
and the corresponding PE-labeled or APC-labeled dextramer peptide-HLA class I
complexes from Immudex (Copenhagen, Denmark) were used for virus-specific T
cell functional assays.
Anti-Human CD3 (BD Horizon™ PE-CF594, clone HCHT1, 1:200, Cat#
562280); Anti-Human CD3 (BD Horizon APC-R700, clone HCHT1, 1:200,Cat#
565119); Anti-Human CD3 (PE/Cy7, clone HIT3a, BioLegend, 1:100, Cat#300316);
Anti-Human CD8 (PE-Cy™7, clone RPA-T8, BD Biosciences, 1:100, Cat#557746);
Anti-Human CD8 (CD8-AlexaFluor®700, clone RPA-T8, BD Biosciences, 1:50,
Cat#557945); Anti-Human CD8 (PerCP, clone BW135/80, Miltenyi Biotec, 1:200,
Cat#130-113-160); Anti-Human CD8 (BD Pharmingen™ APC-H7, clone SK1, BD
Biosciences, 1:50, Cat# 560179); Anti-Human CD4, PE, clone RPA-T4, BD
Biosciences, 1:50, Cat# 555347); Anti-Human CD4, AlexaFluor®647, clone RPA-
T4, BD Biosciences, 1:50, Cat#557707); Anti-Human IFN-γ (APC-R700, clone B27,
BD Biosciences 1:200, Cat# 564981); Anti-Human IL-2 (APC, Clone MQ1-17H12,
BD Biosciences, 1:50, Cat# 554567); Anti-Human CD279 (PD-1) (PE/Cy7, clone
EH12.2H7, BioLegend, 1:20, Cat# 329918); Anti-Human TNF-α (FITC, Clone cA2,
Miltenyi Biotec, 1:200, Cat# 130-091-650); Anti-Human Glut1 (FITC, Clone #
202915, R&D Systems, 1:20, Cat# FAB1418F); Anti-Phosphorylated Human p38
MAPK (pT180/pY182) (PE-Cy7, Clone 36/p38, BD Biosciences, 1:20, Cat#
560241); Anti-Human p53 (FITC, Clone DO-7, BioLegend, 1:20, Cat# 645804);
Anti-Human phospho-p53 (S15) (PE, Clone 261352, R&D Systems, 1:50, Cat#
IC1839P); Anti-Human phospho-ATM (Ser1981) (PE, Clone 10H11.E12,
BioLegend, 1:100, Cat# 651204); Anti-Human dimethyl-Histone H3 (Lys9)
(AlexaFluor®488, Merck Millipore, 1:100, Cat# FCABS301A4); Anti-Human
acetyl-Histone H3 (PE, Merck Millipore, 1:100, Cat# FCABS325PE); Anti-Human
HLA-A2 (PE, Clone BB7.2, BioLegend, 1:200, Cat# 343306), and the viability probe
7-AAD (BD Biosciences) were used for T cell staining. LEAF purified anti-CD3
(clone HIT3a, BioLegend) and anti-CD28 (clone CD28.2, BioLegend) were used for
overnight T cell stimulation. All dextramers and antibodies were used according to
the manufacturer’s instructions.
Isolation of PBMCs and cell sorting. PBMCs were isolated from fresh heparinized
blood by Ficoll-Hypaque density gradient centrifugation and cryopreserved in
liquid nitrogen until the day of analysis. After thawing, CD8+ T cells were isolated
from PBMC with the CD8+ T Cell Isolation Kit (Miltenyi Biotec) and labeled with
the viability probe 7-AAD, anti-CD3, anti-CD8, and HLA-Class I dextramers to
identify antigen-specific T cell sub-populations. CD8-dextramer-positive T cells
were subsequently sorted (yield 500–2000 cells per sample) with a FACSAria III
Cell Sorter (BD Biosciences).
Microarray data acquisition. RNA was purified from dextramer-sorted CD8+
T cells with the Nucleospin RNA XS kit (Macherey Nagel, Duren, Germany),
according to the manufacturer’s instructions. Total RNA concentration was
determined using a Nanodrop spectrophotometer and/or with the Ribogreen RNA
quantification kit (ThermoFisher). RNA integrity was evaluated with the Bioana-
lyzer 2100 traces system (Agilent Technologies). Total RNA was amplified with the
Transplex Whole Transcriptome Amplification (WTA2) kit (Sigma) and purified
with GenElute PCR Clean-Up silica spin-columns (Sigma) following manu-
facturer’s instructions. cDNA was labeled with the ULS Fluorescent Labeling kit
(Agilent Technologies) and hybridized to 60-mer oligonucleotide whole-human-
genome microarrays (Human GE 4 × 44K v2, Agilent Technologies), as indicated
in the manufacturer’s protocol. Microarray slides were scanned with an Agilent
dual-laser DNA microarray scanner. The Agilent Feature Extraction software with
default settings (user manual version 7.5) was used to obtain normalized expression
values from the raw scans.
Microarray data analysis. The GeneSpring GX v11.5 software package (Agilent
Technologies) was used for quality control checks, data normalization by the
quantile method and initial microarray data analysis. Probes detectable in at least
two-thirds of the replicates for each condition were retained for further analysis.
ANOVA test with Benjamini–Hochberg correction for multiple testing (FDR ≤
0.05) was used to select genes differentially expressed among all conditions. These
were visualized as hierarchical clustering and used for principal component ana-
lysis (PCA), to which ‘mean-center’ and ‘scale to unit standard deviation’ options
were applied. Heat maps were generated using the MT4 Multi-Experiment
Viewer71.
Topological pathway analysis was performed separately on the T1 and T2 time-
points datasets with Clipper method72, a two-step empirical approach
implemented in the GraphiteWeb tool73, that uses Gaussian graphical models to
identify pathways with means or covariance matrices significantly different
between two experimental conditions. Specifically, following pathway structure
conversion into nodes (i.e., genes) and edges (i.e., gene connections) graphical
representation using biologically driven rules (KEGG and Reactome databases),
mean and covariance matrices were calculated for chronic and self-limited patients
at each time-point assuming a Gaussian distribution and taking into account the
constraints imposed by the graph structure. After graph decomposition into cliques
(i.e., small connected components), separate likelihood ratio tests were used to
compare the means and covariance matrices of the two groups and to identify the
most altered (i.e., dysregulated) portions (sub-networks) of each pathway. The
p-values derived from this second step of analysis were corrected for multiple
testing with the Benjamini-Hochberg method, thereby generating the
corresponding q-values. Pathways with q-values ≤ 0.05 either in mean or
covariance were deemed as significant and genes associated to individual
dysregulated subnetworks were selected for further analysis.
Overrepresentation analysis was performed on log2 expression data (all detected
probes) using the Gene Set Enrichment Analysis (GSEA) software74 to identify
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molecular pathways significantly overrepresented among the upregulated and
downregulated genes, and to compare the resulting expression profiles with those
of previously published studies. To this end, we used the Molecular Signature
Database v 6.0 (C2, canonical pathways; C5, Gene Ontology, GO, gene sets)
available at http://www.broadinstitute.org/gsea/msigdb/index.jsp. Gene sets smaller
than 15 or larger than 500 genes were excluded; gene sets passing this filter were
considered as significantly enriched if the False Discovery Rate (FDR), calculated
using Signal2Noise as metric and 1000 permutations of gene sets, was ≤0.1. The
permutation type was set to ‘gene set’, instead of ‘phenotype’, as suggested for fewer
than seven replicates; default settings were applied to all other options.
The leading-edge subset analysis was performed to identify the genes in the
ranked list of a functional gene set that appear at, or before, the point where the
running sum reaches its maximum deviation from zero (enrichment score)74. The
genes within this subset can be interpreted as the most important in the
enrichment of the functional gene set. Grouping of terms in categories was then
performed by applying the Enrichment map in Cytoscape75,76 to leading edge
genes deriving from enriched terms with FDR ≤ 0.1. An edge-weighted force-
directed layout method applied to the combined score attribute was used for
graphical representation.
To identify candidate regulatory genes at T1 time point, leading-edge genes
present in at least five of the eight categories were retained, and the Search Tool for
the Retrieval of Interacting Genes (STRING v10.5) database was used to build the
functional gene association network which was visualized by Cytoscape76,77.
EpiFactors (http://epifactors.autosome.ru)43, a web-accessible, manually curated
database that provides information on human proteins and complexes involved in
epigenetic regulation, was used to generate expression profiles of the main
chromatin-regulator complexes.
In Fig. 6d the listed complexes are: APOB mRNA editosome also known as the
Apolipoprotein B mRNA editing enzyme complex; CAF-1, Chromatin Assembly
Factor-1; CoREST, REST Corepressor 1; CREST-BRG1, transcription activator
BRG1; DUB, histone deubiquitination complex; Exosome, RNA exosome complex;
FACT, histone chaperone that FAcilitates Chromatin Transcription; HAT, Histone
acetyltransferases; HDAC, histone deacetylases; HMT, Histone Methyltransferases;
Ino80, chromatin-remodeling ATPase INO80; ISWI, SWI/SNF-Related Matrix-
Associated Actin-Dependent Regulator of Chromatin A5; L3MBTL1, Histone
Methyl-Lysine Binding Protein; MLL, Histone-lysine N-methyltransferases; PcG
and PcG-like, Polycomb Group complexes; PP, dephosporylation complex
phosphatases; SRCAP, multiprotein chromatin-remodeling complex; SWI/SNF,
SWItch/Sucrose Non-Fermentable nucleosome remodeling complex; and SWR,
SWR1-like complex.
Expression data are available at NCBI GEO: GSE111449.
Quantitative PCR. Expression levels of a subset of modulated genes were indepen-
dently determined by Taqman gene-expression assays (Life Technologies) using the
same amplified cDNAs used for microarray analysis, as starting material. The selected
genes included PDCD1 (assay Hs00169472_m1) and BATF (assay Hs00232390_m1);
GAPDH (Hs02758991_g1) served as a loading and normalization control. The
expression levels of nine additional genes—TBX21 (Hs.PT.56a.20216516), CTLA4
(5′UTR-EX1 custom: F: 5-TCCTTGATTCTGTGTGGGTTC-3, R: 5-TTTATGGGA
GCGGTGTTCAG-3, probe: 5-ACACATTTCAAAGCTTCAGGATCCTGA-3), HeyL
(Hs.PT.58.3223619), PCCB (Hs.PT.58.40514946), PGAP3 (Hs.PT.58.38411960),
PRKAG1 (Hs.PT.58.40441800.gs), LAT (Hs.PT.58.39778311), AKT1 (Hs.PT.58.
38430799.g), ZAP70 (Hs.PT.58.2646227.g), and ADCY4 (Hs.PT.58.39234436.g)—were
determined by PrimeTime qPCR 5′ Nuclease Assays (IDT, Coralville, IA) using the
relative quantification method; also in this case, GAPDH served as a reference
housekeeping gene.
Glucose uptake and GLUT1 assay. Glucose uptake assays were done on PBMC
stimulated overnight with coated anti-CD3 (10 μg/ml) and soluble anti-CD28 (2
μg/ml) for ex vivo analysis. To study inhibition by specific chemical compounds,
PBMCs were stimulated for 40 h with virus-specific peptides. After specific sti-
mulation, PBMCs were washed with PBS 1X to eliminate endogenous glucose and
stained for 30 min at 37 ° C with the glucose analog 2-NBDG (2-deoxy-2-[(7-nitro-
2,1,3-benzoxadiazol-4-yl) amino]-D-glucose, ThermoFisher; 40 μM) in glucose-free
RPMI with 10% dialyzed FBS, and finally stained with the viability probe 7-AAD.
Fluorescence generated by the glucose analog, which is proportional to glucose
uptake, was measured with a FACSCANTO II multicolor flow cytometer and
analyzed with DIVA (BD Biosciences) and FlowJo (Tree Star) softwares.
GLUT 1 assay was performed on PBMCs, after specific stimulation as described
above, by using an anti-glucose transporter GLUT1 antibody (Glut1-FITC, R&D
Systems). Cells were surface-stained, fixed with the fixation reagent-medium A
(Nordic MUbio), then permeabilized with the permeabilization reagent-medium B
(Nordic MUbio) and stained with the anti-glucose transporter GLUT1 antibody
(R&D system), according to the manufacturer’s instructions, and finally analyzed
by flow cytometry.
Glucose level measurement. The glucose level was measured with the Glucose
Assay kit (Beckman Coulter) in cell culture media from total CD8+ T cells purified
with the CD8+ T Cell Isolation Kit (Miltenyi Biotec). CD8+ T cells were cultured
overnight with or without virus-specific peptides (NS3-specific or FLU-/EBV-/
CMV-specific peptides). A Beckman Coulter AU5400 analyzer was used, in
accordance with the manufacturer’s instructions.
Mitochondrial membrane potential and mitochondrial superoxide assays.
MMP was determined on PBMCs stimulated overnight with coated anti-CD3
(10 μg/ml) and soluble anti-CD28 (2 μg/ml) for ex vivo analysis by using the
potentiometric probes JC-1 (Molecular Probes, Life Technologies). After surface
staining, cells were incubated with JC-1 (2.5 μg/ml) for 15 min at 37 °C and pro-
tected from light before flow-cytometry analysis. Samples were then stained with
the viability probe 7-AAD and finally acquired on a FACSCANTO II multicolor
flow cytometer and analyzed with the DIVA software (BD Biosciences). The
decrease in JC-1 fluorescence caused by co-treatment (15 min at 37 °C) with the
protonophores valinomycin or carbonyl cyanide m-chlorophenyl hydrazine
(CCCP) (Molecular Probes) served as a positive control for MMP depolarization.
Dextramer-positive virus-specific depolarized cells were quantified by subtracting
the percentage of FL1high/FL2low cells (JC-1 staining) detected in the unstimu-
lated samples from the percentage of the corresponding cell subsets detected in the
stimulated samples23.
Mitochondrial superoxide levels were measured on PBMCs incubated overnight
with coated-anti-CD3 (10 μg/ml) and soluble anti-CD28 (2 μg/ml) or with NS3-
specific peptides in the presence or absence of the antioxidant resveratrol (10 μM).
ROS levels were also measured after 10 days of culture with virus-specific peptides.
After specific stimulation, PBMCs were washed, analyzed for viability with the with
the LIVE/DEAD Far Red Dead Cell Stain Kit (ThermoFisher), subsequently stained
for cell surface markers and then incubated with the MitoSOX Red dye (5 μM;
ThermoFisher) for 15 min at 37 °C, according to the manufacturer’s protocol,
before flow cytometry acquisition23.
Cytoplasmic ROS (DHE, H2DCFDA staining). Cytoplasmic ROS levels were
determined on PBMC stimulated at the same culture conditions described for
mitochondrial ROS. Cells were analyzed for viability with the LIVE/DEAD Far Red
Dead Cell Stain Kit (ThermoFisher), stained for cell surface markers, then incu-
bated with the superoxide sensitive dye dihydroethidium (DHE, 1 µM, Thermo-
Fisher) or with the H2O2 sensitive dye 2′,7′-dichlorodihydrofluorescein diacetate
(H2DCFDA, 2 µM, ThermoFisher), according to the manufacturer’s protocol, and
finally analyzed with FACSCANTO II multicolor flow cytometer. Data were ana-
lyzed with DIVA (BD Biosciences) and FlowJo (Tree Star) softwares.
Phosphoprotein staining. Phosphoproteins and nuclear factors were measured
on PBMC either unstimulated or incubated overnight with coated-anti-CD3
(10 μg/ml) and soluble anti-CD28 (2 μg/ml) or with NS3-/FLU-CMV-EBV-specific
peptides in the presence or absence of the antioxidant resveratrol (10 μM).
For anti-phospho-ATM, anti-dimethyl-Histone H3 (Lys9), anti-acetyl-Histone
H3 intracellular antibody detection, intracellular staining BD Phosflow™ Fix and
Perm/Wash Buffer I (BD) was used, according to the manufacturer’s instructions.
For anti-phospho-p38, anti-total p53 and anti-phospho-p53 antibody detection,
the intracellular staining Fixation/Permeabilization Solution Kit (Cytofix/
Cytoperm BD) was used, according to the manufacturer’s instructions.
Data were collected with a FACSCANTO II multicolor flow cytometer and
analyzed with DIVA (BD Biosciences) and FlowJo (Tree Star) softwares.
Seahorse analysis. Seahorse experiments were performed on total CD8+ T cells
purified with the CD8+ T Cell Isolation Kit (Miltenyi Biotec). Multiple stimuli (i.e,
Flu-/EBV-/CMV-specific and NS3-specific HCV peptides, plus an unstimulated
control) were applied to CD8+ T cells from each individual patient and each
culture condition was analyzed in the same experimental session in order to limit
possible batch effects. These were further minimized through the internal nor-
malization of maximal to basal OCR and ECAR values that was applied to each
sample. Specifically, purified CD8+ T cells were cultured overnight with or without
virus-specific peptides and then seeded on Seahorse XFp cell culture miniplates
(300,000 cells/well). Briefly, cells were plated on poly-D-lysine-(100 μg/ml) coated
8-well polystyrene Seahorse miniplates and assayed for OCR (pmol/min) and
ECAR (mpH/min) at the basal level and after sequential addition of oligomycin
(1 μM), FCCP (2 μM), and antimycin A/rotenone (1 μM/0.1 μM), according to the
manufacturer’s protocol. To determine the maximum glycolytic capacity (MGC)
and glycolytic reserve (GR; i.e., the difference between MGC and baseline ECAR)
values of basal and oligomycin-modulated ECAR were used. Specifically, oligo-
mycin blocks mitochondrial complex V, providing indication of the amount of
oxygen utilized for ATP synthesis; FCCP uncouples ATP synthesis from the
electron transport chain by transporting protons across the inner mitochondrial
membrane, thereby allowing the calculation of the maximal and the spare
respiratory capacity; rotenone/antimycin A shuts down mitochondrial respiration
by blocking complexes I and III, allowing to calculate the ATP production, the
maximal (MRC), the spare respiratory capacity (SRC), the proton leak and the
coupling efficiency of virus-specific CD8+ T cells. Results were obtained with the
Agilent Seahorse XF Report Generator of the Wave 2.3 software, according to the
manufacturer’s instructions.
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Aggresome detection (ProteoStat staining). For the detection of protein
aggregates, after overnight PBMC stimulation with or without coated anti-CD3
(10 μg/ml) and soluble anti-CD28 (2 μg/ml), cells were surface stained and then the
ProteoStat Aggresome Detection Kit (Enzo Life Sciences, New York, NY) was used
according to the manufacturer’s protocol, before flow cytometry acquisition25.
Cells treated with 5 μM of proteasome inhibitor (MG-132) served as positive
controls. Aggresome levels were quantified by subtracting ProteoStat median
fluorescence intensity (MFI) in the unstimulated from the stimulated samples. Data
were collected with a FACSCANTO II multicolor flow cytometer and analyzed
with DIVA (BD Biosciences) and FlowJo (Tree Star) softwares.
T cell expansion, inhibitory compound treatment, and cytokine production
assays. Short-term T cell lines were generated by 10 days PBMC stimulation with
HCV-NS3 or with HLA-A2-restricted HCV peptides (each at the final 1 μM
concentration) in the presence or absence of drug inhibitors. For ex vivo analysis of
inhibitor activity, PBMCs were stimulated for 40 h with HCV-NS3 peptides. FLU,
CMV and EBV peptides were used as controls. At the end of the culture period,
cytokine determination (IFN-γ, TNF-α and IL-2) was performed by intracellular
cytokine staining23. Specifically, brefeldin-A (10 μg/ml; Sigma-Aldrich) was added
to the cells and left throughout the time of stimulation for ex-vivo assays and for
the last 4 h of the 10-days cultures. After washing, cells were stained with anti-CD8,
anti-CD4 and anti-CD3, fixed and permeabilized (FIX&PERM Cell Fixation and
Permeabilization Kit, Nordic-MUBio) to allow intracellular detection of IFN-γ,
TNF-α, and IL-2.
Inhibitors tested. The following compounds were used to restore intracellular
signaling, metabolic functions and anti-viral activities: the kinase ATM inhibitor
KU-55933 (tested at concentrations of 0.01–0.1 μM, Sigma), the p53 inhibitor
Pifithrin-α (tested at concentrations of 10–30 μM, Sigma), the p38 inhibitor
SB203580 (tested at concentrations of 0.01–0.1 μM, Sigma), the AMPK inhibitor
Dorsomorphin (tested at concentrations of 0.1–1 μM, Sigma), the EZH2 inhibitor
GSK126 (0.1–0.05 μΜ, Selleckchem), the EZH2 inhibitor EPZ005687 (0.1–0.05 μΜ,
Selleckchem), the G9A inhibitor UNC0638 (0.1–0.5 μΜ, Selleckchem), the G9A
inhibitor BIX01294 (0.5–1 μΜ, Selleckchem), and Resveratrol38,39 (5–10 μΜ,
Sigma). Cell toxicity by the inhibitory compounds was assessed by analyzing
increased cell death by flow cytometry.
Flow cytometry measurement controls. As a negative control (in gray in Sup-
plementary Fig. 15) for all cytofluorimetric measurements, a sample without the
staining of interest has always been acquired in order to define the level of auto-
fluorescence related to background signals. This provides a measure of the fluor-
escence spread from the other staining parameters into the channel of interest and
allows to determine accurately the threshold for positive staining, in accordance
with accepted guidelines78.
Statistical analysis. The GraphPad Prism 6.0, JASP 0.10.2 (https://jasp-stats.org/)
and Jamovi 1.0.7 (https://www.jamovi.org) softwares were used for statistical
analysis. The F test of variance was applied to the different groups; normality
distribution of data was tested by the Kolmogorov-Smirnov test. Differences
between multiple patient groups have been evaluated by Kruskal-Wallis non-
parametric test and the p-values have been calculated and corrected for pair-wise
multiple comparisons, according to the methods of Dunn.
Moreover, to detect differences in treatments the Friedman non-parametric test
has been applied and corrected for pair-wise multiple comparisons, according to
the Conover test. In the experiments with the different inhibitory compounds, the
significance of the fold change (FC) upon drug treatments was evaluated by the
Wilcoxon signed-rank tests (different from a theoretical median= 1).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All transcriptomic data from this study have been deposited in the National Center for
Biotechnology Information Gene Expression Omnibus (GEO) and are accessible through
the GEO Series accession code GSE111449. Raw data are provided as Source Data File
and all other relevant data are available from the corresponding author on request.
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